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Abstract 
Increased levels of soluble endoglin (Sol-Eng) correlate with poor outcome in 
human cancer. We have previously shown that shedding of membrane endoglin, and 
concomitant release of Sol-Eng is a late event in chemical mouse skin carcinogenesis 
associated with the development of undifferentiated spindle cell carcinomas (SpCCs). In 
this report, we show that mouse skin SpCCs exhibit a high expression of hepatocyte 
growth factor (HGF) and an elevated ratio of its active tyrosine kinase receptor Met vs 
total Met levels. We have evaluated the effect of Sol-Eng in spindle carcinoma cells by 
transfection of a cDNA encoding most of the endoglin ectodomain or by using purified 
recombinant Sol-Eng. We found that Sol-Eng inhibited both mitogen-activated protein 
kinase (MAPK) activity and cell growth in vitro and in vivo. Sol-Eng also blocked 
MAPK activation by transforming growth factor-1 (TGF-1) and impaired both basal 
and HGF-induced activation of Met and downstream MAPK. Moreover, Sol-Eng 
strongly reduced basal and HGF-stimulated spindle cell migration and invasion. Both 
Sol-Eng and full-length endoglin were shown to interact with Met by 
coimmunoprecipitation experiments. However, full-length endoglin expressed at the 
plasma membrane of spindle carcinoma cells had no effect on Met signaling activity, 
and was unable to inhibit HGF-induced cell migration/invasion. These results point to a 
paradoxical suppressor role for Sol-Eng in carcinogenesis.  
 
 
 
 
 
3 
 
 
 
Summary 
 
The ectodomain of the TGF- coreceptor endoglin (CD105) is shed into the 
circulation and is called soluble endoglin (Sol-Eng). Here, we show that Sol-Eng blocks 
Met signaling activity and stimulation of spindle carcinoma cell migration/invasion by 
its ligand HGF.  
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Introduction 
 Many cell-surface membrane receptors are proteolitically cleaved at their 
juxtamembrane region in a process called “shedding”, which results in the release of the 
ectodomain into the extracellular space. Shedding may downregulate receptors at the 
cell surface and generate soluble forms that either antagonize or favor the formation of 
active signaling complexes with ligands (1). Endoglin (CD105) is a membrane 
glycoprotein that acts as a coreceptor for members of the transforming growth factor- 
(TGF-) superfamily, including TGF-1, TGF-3, activin-A, BMP2, BMP7, BMP9 and 
BMP10 (2). Endoglin plays a crucial role in cardiovascular development and 
angiogenesis (3, 4). Mutations in the endoglin gene are responsible for the hereditary 
hemorrhagic telangiectasia type 1 (HHT1), a vascular disorder characterized by 
epistaxis, cutaneous telangiectases and arteriovenous malformations in brain, lung and 
liver (5). In cancer, endoglin has also emerged as an important modulator of malignant 
progression by influencing tumor cell proliferation, motility, invasion and metastasis 
(reviewed in refs. 2, 6). Thus, endoglin behaves as a suppressor of malignancy in skin, 
esophageal, prostate and breast carcinomas (7-10), while promotes tumor growth and 
invasiveness in Ewing sarcoma and melanoma (11). 
A soluble endoglin form (Sol-Eng) resulting from the cleavage of full-length 
endoglin by the membrane-anchored matrix metalloprotease MMP14 has been detected 
in the circulation associated with different pathologies, including preeclampsia and 
cancer (12-14). Preeclampsia is a specific syndrome of pregnancy characterized by 
hypertension and proteinuria, which is linked to elevated levels of Sol-Eng and 
placenta-derived soluble VEGF receptor 1 (also known as soluble fms-like tyrosine 
kinase-1, sFlt1) (15). Sol-Eng inhibits angiogenesis (12, 14) and increases blood 
pressure and vascular permeability (13, 14). Whereas it has been proposed that these 
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effects are mediated by Sol-Eng trapping circulating TGF-1, thus impairing its binding 
to the functional receptors (14), other authors have found that Sol-Eng binds directly 
and with high affinity BMP9 and BMP10, but not TGF-1 or TGF-3 (16, 17). Sol-Eng 
has also been detected in the plasma, serum and urine of cancer patients. Interestingly, 
elevated levels of circulating Sol-Eng is a bad prognostic factor in breast, colorectal and 
prostate cancer that correlates with metastasis (18-21). We have shown that cleavage of 
membrane endoglin, and concomitant generation of Sol-Eng occurs during progression 
of chemical mouse skin carcinogenesis, which is associated with the development of 
highly malignant undifferentiated spindle cell carcinomas (SpCCs) (22). Though 
Hawinkels and coworkers suggested an anti-angiogenic role for Sol-Eng in the tumor 
microenvironment (12), the function of Sol-Eng in carcinogenesis remains to be 
determined. 
Hepatocyte growth factor (HGF) signaling through its membrane tyrosine kinase 
receptor Met plays an important role during embryonic development and tissue 
remodeling. Yet, HGF/Met aberrant signaling is also associated with cancer, since Met 
hyperactivation promotes different processes related to malignant progression, including 
tumor cell proliferation, migration, invasion, metastasis and angiogenesis (23, 24).  
In this work, we show that mouse spindle cell carcinomas generated by chemical 
carcinogenesis express elevated levels of HGF. Sol-Eng, but not membrane-bound full-
length endoglin, inhibited baseline and HGF stimulated Met signaling, impairing 
proliferation, migration and invasion of spindle carcinoma cells. These results suggest 
an anti-oncogenic role for Sol-Eng in carcinogenesis. 
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Materials and methods 
Cell culture conditions and treatments  
The origin and characteristics of the mouse epidermal cell lines used in this work 
are summarized in Supplementary Table 1 (available at Carcinogenesis Online). 
MCA3D and PB cells were kindly provided by Dr. S. Yuspa (National Cancer Institute, 
Bethesda, USA); PDV cells by Dr. NE Fusenig (German Cancer Research Center, 
Heidelberg, Germany); HaCa4, MSC11A5, CarB and CarC cells by Dr. A. Balmain 
(University of California, San Francisco, USA). CarC, the cell line most profusely used 
in this work, was derived from a poorly differentiated mouse skin carcinoma induced by 
chemical carcinogenesis (25). CarC was tested by microsatellite marker polymorphism 
analysis and found free of any contaminating cell (26). Cells were grown in Ham’s F12 
medium supplemented with amino acids and vitamins (MCA3D, PB, PDV, HaCa4) or 
Dulbecco’s modified Eagle’s medium (CarB, CarC, MSC11A5), in 10% fetal bovine 
serum and antibiotics (2.5 g/ml amphotericin B, 100 g/ml ampicillin, 32 g/ml 
gentamycin) (Gibco). Cultures were maintained on plastic at 37ºC in a 5% CO2-
humidified atmosphere. 
For TGF-1 and HGF treatments, recombinant human TGF-1 and HGF 
(PreproTech EC) were added to CarC cell transfectants growing in the absence of serum 
at the indicated concentrations. Treatments with recombinant human Sol-Eng (rhSol-
Eng) were performed by pre-incubating cells with the indicated concentrations of rhSol-
Eng (R&D Systems) for 1 h. 
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Plasmids and transfections 
The HA-tagged human endoglin cDNA in pDisplay (27) was used to derive by 
PCR a truncated endoglin construct encoding a soluble form encompassing the orphan 
domain and the ZP-N domain (amino acids 26-437). The 1.3-kb PCR product was 
cloned into pCRII-TOPO (Invitrogen) and the endoglin fragment was inserted into the 
EcoRI site of the pCAGGS plasmid under the control of a ubiquitous actin promoter 
resulting in the pCAGGS-Sol-Eng vector (13). The plasmid pSV2neo (Clontech) 
contains a neomycin resistance gene.  
CarC cells were co-transfected with pCAGGS-Sol.Eng and pSV2neo vectors at a 
10:1 ratio, as described (28). Briefly, 10 g of plasmid DNA were mixed with 20 g of 
Lipofectamin (Life Technologies, Inc.) in serum-free medium according to the protocol 
provided by the manufacturer. Positive clones were selected in the presence of 400 
g/ml of the antibiotic G418 and screened for the presence of soluble endoglin using a 
commercial ELISA kit (Quantikine Human Endoglin/CD105, R&D Systems). Two 
clones expressing/secreting substantial amounts of Sol-Eng (CSE1 and CSE3) were 
selected for further studies. Parallel transfections with pSV2neo alone yielded endoglin-
negative mock transfectants. Pooled clones were used for biochemical and functional 
studies. 
HEK-293T cells were transiently cotransfected with cDNAs encoding the full-
length wild-type human c-Met in pBABE puro vector (Addgene plasmid 17493; see ref. 
29) and a cDNA encoding either the full-length human endoglin or its whole 
extracellular domain (amino acids 26-586, including the orphan domain and ZP-N and 
ZP-C domains), both tagged with HA, in pDisplay, as previously described (30). Cells 
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were lysed 24 h after transfection and protein expression was determined by Western 
blotting and coimmunoprecipitation experiments.    
Stable transfection of the cDNA encoding the full-length human L-endoglin 
isoform subcloned into the pcDNA3 expression vector was carried out as previously 
described (22). CarC-Eng cells expressing endoglin at the plasma membrane were 
selected using a FACS Vantage cell sorter (Becton Dickinson). CarC cells transfected 
with the empty vector (CarC-neo) were used as a control. 
Real-time quantitative RT-PCR analysis 
 RNA from tissues and cell lines was obtained using the RNeasy kit (Qiagen). 
Quantitative reverse transcription-PCR analysis was performed using the iScript 
Reverse Transcription Supermix kit (BioRad) in a 7900HT Fast (Life Technologies) 
instrument. The ribosomal protein RPLPO was used as an internal control of RNA 
quality and amplification. Taqman probes for HGF (Mm01135193-m1) and Met 
(Mm01156972-m1) were from Life Technologies. 
Western blot and coimmunoprecipitation experiments 
 For detection of proteins in Western blots, cells were lysed at 4ºC in modified 
RIPA buffer and a cocktail of protease (2 g/ml aprotinin; 2 g /ml leupeptin; 1 mM 
phenylmethylsulfonil fluoride) and phosphatase (1 mM sodium orthovanadate; 2 mM -
glycerophosphate; 0.2 mM sodium fluoride) inhibitors (Sigma-Aldrich). Proteins were 
separated by sodium dodecyl sulfate-polyacrilamide gel electrophoresis and then 
transferred to Immobilon-P membranes (Millipore). For immunodetection of proteins, 
the following antibodies were used: 12CA5 mAb (Roche Diagnostics) for HA-Sol-Eng; 
P4A4 mAb (Santa Cruz Biotechnology) for human full-length endoglin (7); the mAb 
1D4 recognizing glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was purchased 
9 
 
 
from Enzo Life Sciences AG; the Abs specific for p44/42 MAPK (ERK1/2) (#9102), 
phospho-p44/42 MAPK (Thr202/Tyr204) (#9101S), as well as a mAb specific for 
phospho-Met (Tyr1234/1235) (D26) (#3077), all were from Cell Signaling; a polyclonal 
Ab recognizing Met (sc-162) was from Santa Cruz Biotechnology Inc. Appropriate 
secondary Abs coupled to horseradish peroxidase were used. Peroxidase activity was 
developed using an enhanced chemiluminiscence kit as indicated by the manufacturer 
(Pierce).  
 For coimmunoprecipitation experiments, cells were lysed in IP buffer (50 mM 
Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP40) with a cocktail of protease 
inhibitors. Tagged Sol-Eng and Met were immunoprecipitated using anti-HA mAb 
(Roche Diagnostics) and anti-Met Ab sc-162 (Santa Cruz Biotechnology Inc.), 
respectively.   
Cell growth, migration and invasion assays 
 For growth assays, cells were plated in triplicate in a 24-wells/plate at a density 
of 30,000 cells/well and grown in the absence of serum (with or without TGF-1) for 
the indicated times. The relative number of cells was determined by staining with 
crystal violet and spectrophotometric reading (560 nm) of the solubilized dye. For cell 
proliferation assays, cells were seeded in 96 wells/plate at a density of 10,000 cells/well 
and grown in the presence or absence of serum for the indicated times. Incorporation of 
5-bromo-2’-deoxyuridine (BrdU) was determined by using the Cell Proliferation ELISA 
BrdU kit (Roche Diagnostic). 
 Transwell migration assays were performed using Transwell chambers with 8-
m-pore polycarbonate filters (Corning) coated or not with 30 g of Matrigel (Becton 
Dickinson). Cells were seeded in the upper compartment (4x104 cells per well) in 
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medium without serum and allowed to transmigrate for 15 h at 37ºC using 10% FBS, in 
the presence or absence of 100 ng/ml HGF, as chemoattractant. Cells on the upper side 
of the Transwell were then removed and those on the underside were fixed with 
methanol and stained with 1 g/ml solution of 4’,6-diamino-2-phenylindol (DAPI). Cell 
migration was quantified by counting the number of cells that migrated through the 
inserts. Four-five different fields were counted using an Axiophot fluorescence 
microscope (Carl Zeiss).  
Chemical carcinogenesis and tumorigenicity assays 
 All animal experiments were approved by the Animal Care and Use Committees 
of the CSIC and UAM. Mice were cared for following institutional guidelines for 
animal care and in accordance with the standards established in the National Institutes 
of Health Guide for the Care and Use of Laboratory Animals. Induction of mouse skin 
tumors by initiation with a single dose of 7,12-dimethylbenz(a)-anthracene (DMBA) 
and promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA) for 15 weeks has been 
previously described (22). Tumors were histologically typed by H&E staining of 
paraffin sections as well as by RT-PCR analysis of the following 
differentiation/progression markers: i) loss of K1/K10 expression in squamous cell 
carcinomas (SCCs); ii) induction of SPARC during progression from papillomas to 
SCCs; and iii) accumulation of Snail1 transcripts in poorly differentiated SpCCs. 
For tumorigenicity assays, 1-2x106 cells were i.d. injected into the two flanks of 
8-10 weeks-old female athymic nude mice (Harlan). The size of tumors was calculated 
from caliper measurements of two orthogonal diameters at different times. Tumors were 
excised and immediately frozen in liquid nitrogen for Western blot analysis and real-
time RT-PCR. 
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Statistical analysis 
 Data are presented as mean + SEM. Significance was determined using the 
Student’s t test. Differences were considered significant at p < 0.05. 
 
Results 
Sol-Eng attenuates MAPK signaling activity and inhibits cell proliferation of spindle 
carcinoma cells 
 CarC is a malignant spindle cell line derived from a mouse skin carcinoma 
induced by chemical carcinogenesis (25). CarC has proteolytically inactivated 
membrane endoglin at the cell surface and sheds low baseline levels of Sol-Eng (22). In 
order to ascertain whether the presence of high levels of Sol-Eng in the extracellular 
medium affects CarC behavior, these cells were stably transfected with a cDNA 
encoding human Sol-Eng tagged with hemagglutinin (HA). Two clones (CSE1 and 
CSE3) expressing/secreting substantial levels of Sol-Eng (Fig. 1A, B) were selected, 
and their growth properties compared with those of control cells transfected with an 
empty vector (mock).  Both CSE1 and CSE3 cells showed a slight but significantly 
reduced basal proliferation with respect to mock cells in the presence of serum (Fig. 
1C). As CarC secretes autocrine growth factors, we also studied the growth properties 
of the transfectants in the absence of serum. In this case, reduced growth of CSE1 and 
CSE3 vs mock cells was more evident (Fig. 1D). It can be argued that Sol-Eng while 
being synthesized inside CSE cells could interfere with the cell cycle machinery 
slowing down proliferation. In order to address this possibility, we incubated cells with 
a purified recombinant human Sol-Eng (rhSol-Eng) protein and found that it efficiently 
inhibited both mock and CSE cell growth (Fig. 1E).  
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A slight reduction of cell growth was also observed in vivo after injection of 
CarC cell transfectants into athymic nude mice. Tumors induced by CSE3 (and also 
CSE1 at the first two weeks post-injection) grew slower than those induced by mock 
cells (Fig. 2A). The basis for the different tumorigenic behavior of CSE1 and CSE3 is 
presently unknown since both clones express similar levels of Sol-Eng in vitro (Fig. 1A, 
B) and in vivo (Fig. 2B). CarC cells carry oncogenic mutations in the two alleles of the 
H-Ras gene (26, 31), and display a hyperactivated Ras/mitogen-activated protein kinase 
(MAPK) signaling pathway. Interestingly, CSE1 and CSE3 showed reduced levels of 
phospho-extracellular signal-regulated kinase (ERK)1/2 compared to mock cells both in 
vitro (Fig. 2C) and in vivo (Fig. 2D), whereas no variation was observed in the total 
ERK1/2 expression levels. In vitro, this reduction was more pronounced in CSE3 (Fig. 
2C), which may account for the slightly weaker tumorigenic potential of CSE3 with 
respect to CSE1 (Fig. 2A). 
Sol-Eng blocks TGF-1-induced cell growth 
 In contrast to normal keratinocytes and SCC cells, spindle carcinoma cells are 
not only insensitive to the TGF-1 growth inhibitory response, but their growth is 
stimulated by the cytokine (32). Accordingly, proliferation of mock cells was slightly 
increased by TGF-1 in a dose-dependent manner (Fig. 3A). In contrast, this TGF-1-
dependent growth stimulation did not occur in CSE3 cells. Moreover, TGF-1 at 1 
ng/ml was able to activate the ERK1/2 pathway in mock but not in CSE3 cells (Fig. 
3B). A similar inhibitory effect on the TGF-1-dependent activation of ERK1/2 was 
seen in parental CarC cells pre-incubated with rhSol-Eng (Fig. 3C). These results 
indicate that Sol-Eng inhibits TGF-1 stimulation of MAPK signaling activity in CarC 
spindle cells.  
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Enhanced expression of HGF is a late event in mouse skin chemical carcinogenesis 
Next, we asked whether Sol-Eng could inhibit cell growth and MAPK signaling 
activity triggered by activation of tyrosine kinase receptors. In a search for growth 
factors expressed/secreted by transformed keratinocytes, we found that CarC cells 
express remarkably high levels of hepatocyte growth factor (HGF) mRNA compared to 
other keratinocyte cell lines such as premalignant keratinocytes (MCA3D and PB), SCC 
cells (PDV and HaCa4) and SpCC cell lines (CarB and MSC11A5) (Fig. 4A). As a 
matter of fact, increased levels of HGF transcripts are mainly associated with the 
spindle phenotype during in vivo mouse skin carcinogenesis (Fig. 4B). The transcript 
levels of the HGF receptor Met remain low in transformed keratinocyte cell lines, with 
the exception of MCA3D and MSC11A5 that express relatively high levels (Fig. 4C). In 
vivo, Met expression is increased in SCCs with respect to premalignant stages of 
carcinogenesis, but Met transcript levels appear to diminish in SpCCs (Fig. 4D). 
Interestingly, when the levels of total and phosphorylated Met proteins were analyzed in 
the cell lines, spindle carcinoma cells (CarB, CarC and MSC11A5) showed enhanced 
levels of activated versus total Met protein expression compared to the other cell lines, 
and CarC displayed the highest phospho-Met/Met ratio (Fig. 4E). However, Met 
polypeptides (both the 170-kDa single chain precursor and the 145-kDa product 
corresponding to the -chain of the mature receptor) were clearly downregulated in 
CarC compared to the other cell lines (Fig. 4E). These results might indicate that an 
autocrine loop exists in CarC by which secreted HGF continuously activates Met on the 
cell surface inducing its degradation, and are consistent with reports showing Met 
internalization and degradation induced by HGF (33, 34). 
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Sol-Eng inhibits basal and HGF-induced Met signaling activity and 
coimmunoprecipitates with Met  
Subsequently, we studied the effect of Sol-Eng on basal and HGF-mediated Met 
activation of CarC cells. As shown in Fig. 5A, CSE1 and specially CSE3 cells displayed 
reduced levels of baseline active phospho-Met compared to mock cells. This result is 
consistent with the decreased baseline phospho-ERK1,2 levels and weaker 
tumorigenicity observed in CSE1 and CSE3 cells (Fig. 2A and C). In addition, HGF-
dependent activation of Met and its downstream effector ERK1/2 were blocked in both 
CSE1 and CSE3 cells that express/secrete Sol-Eng (Fig. 5B, C). In mock cells, HGF 
induced the downregulation of Met shortly after stimulation for 5-10 min (Fig. 5B, C). 
Interestingly, baseline Met levels in CSE1 and CSE3 were also reduced with respect to 
mock cells (Fig. 5A-C), suggesting that expression of Sol-Eng induces the 
downregulation of Met. Likewise, preincubation of CarC cells with increasing 
concentrations of rhSol-Eng inhibited stimulation of Met signaling activity by HGF and 
downregulated Met levels in a dose-dependent manner (Fig. 5D). We next studied 
whether full-length human endoglin (Eng) was able to inhibit HGF stimulation of Met 
signaling. As shown in Figure 5E, Eng stably expressed at the plasma membrane of 
CarC cells (22) was unable to inhibit HGF-induced phosphorylation of both Met and 
ERK1/2. Also, Met protein levels were not affected by expression of full-length 
endoglin, but were down-regulated upon stimulation with HGF, as expected (Fig. 5E).  
In order to ascertain whether Sol-Eng interacts with Met, we performed 
coimmunoprecipitation analysis. To this end, HEK-293T cells were cotransfected with 
constructs encoding Sol-Eng tagged with HA and untagged Met. Immunoprecipitation 
with anti-Met antibody clearly coprecipitated HA-Sol-Eng (Fig. 5F, upper panel), 
whereas a weaker coprecipitation signal of Met with anti-HA-Sol-Eng was detected 
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(Fig. 5F, lower panel). We also cotransfected constructs encoding Met and either Sol-
Eng or full-length Eng, both tagged with HA, in HEK-293T cells. Interestingly, Met 
immunoprecipitation coprecipitated both full-length and truncated soluble endoglin 
proteins (Fig. 5G).  
Sol-Eng impairs migration/invasion of spindle carcinoma cells 
CarC cells are highly migratory and invasive in vitro and in vivo (35, 36). Using 
Transwell migration assays, in which the filter was coated (invasion) or not (migration) 
with Matrigel, HGF was able to stimulate further CarC cell migration and invasion by 
~1.5 and ~4 folds, respectively, (Fig. 6A, B).  In order to test whether Sol-Eng and full-
length Eng had some effect on this behavior, we compared the migratory/invasive 
abilities of CSE3 and CarC-Eng with that of the parental and control cells before and 
after HGF stimulation. Compared to mock cells, CSE3 showed strongly decreased basal 
migratory and invasive abilities and were refractory to HGF stimulation (Fig. 6C, D). In 
contrast, CarC-Eng cells exhibited a substantial reduction in their migratory capacities 
under basal conditions, and showed only a slight, but non-significant, decreased 
invasiveness (Fig. 6A, B). Interestingly, HGF clearly stimulated cell migration and 
invasion in CarC-Eng and parental/control cells (~2 and ~4 folds, respectively; Fig. 6A, 
B), indicating that whereas Sol-Eng does interfere with Met-mediated CarC pro-
migratory and pro-invasive properties, full-length Eng does not. These results are in 
agreement with the respective abilities of Sol-Eng and full-length Eng to impair or not 
HGF-induced Met signaling activity (Fig. 5).          
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Discussion 
 Membrane endoglin is cleaved in the juxtamembrane region by MMP14 to 
release Sol-Eng into the circulation, and increased levels of Sol-Eng are linked to poor 
prognosis in human breast, colorectal and prostate cancers (reviewed in refs. 2, 6). In 
addition, we found that shedding of membrane endoglin leading to release of Sol-Eng is 
a hallmark of progression to highly aggressive SpCCs during chemical mouse skin 
carcinogenesis (22). In this work, we have studied the effect of Sol-Eng on the behavior 
of CarC, a highly tumorigenic and metastatic spindle carcinoma cell line (35) that has 
hyperactivated the MAPK signaling pathway due to the presence of two mutated H-Ras 
alleles (31, 37). We report that Sol-Eng clearly inhibits MAPK activity and CarC cell 
growth in vitro. Although Sol-Eng was able to inhibit MAPK signaling activity also in 
vivo, its effect on the growth of tumors induced by CarC in nude mice was less 
pronounced (Fig. 2A). This could be due to the undetermined actions of Sol-Eng on 
stromal cells that might compensate the direct growth inhibitory effect exerted by this 
molecule on tumor cells. In this regard, it is also worth emphasizing the active crosstalk 
between stromal and tumor cells by which stromal-dependent epithelial endoglin 
shedding constitutes a mechanism that may exert an environmental control of cell 
malignancy (38). We also show that Sol-Eng counteracts the mild stimulation of CarC 
cell proliferation as well as the further activation of MAPK signaling induced by TGF-
1. The mechanism for this blockade is uncertain since although it has been reported 
that Sol-Eng acts as a scavenger for TGF-1 preventing its binding to the cell surface 
receptors (14), this has been questioned by other laboratories (16, 17). Notwithstanding, 
the most striking observation of the present report is the inhibitory effect exerted by Sol-
Eng on the activation of the tyrosine kinase receptor Met by its ligand HGF. Moreover, 
Sol-Eng strongly inhibited basal and HGF-induced spindle carcinoma cell migration and 
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invasion (Fig. 6). Interestingly, this effect is specific for Sol-Eng as membrane-bound 
full-length Eng was unable to inhibit the activation of Met and its downstream mediator 
ERK1,2 as well as the stimulation of cell migration/invasion by HGF (Figs. 5E, 6A, 
6B). Although full-length Eng significantly reduced basal spindle carcinoma cell 
migration, this effect could be due to the inhibition of TGF-1/Smad3 pro-migratory 
signaling activity (22).  It is well established that HGF induces the internalization of 
Met and its subsequent degradation in the lysosomal compartment (reviewed in ref. 34). 
The fact that both transfected and recombinant Sol-Eng were able to downregulate Met 
in the absence of HGF (Fig. 5B-D), suggests the possibility that Sol-Eng can bind Met 
on the surface of CarC cells and promote its internalization. A schematic model 
depicting the role of HGF-induced Met internalization on Met signaling and the 
hypothetical inhibitory effect exerted by Sol-Eng is presented in Supplementary Fig. 1. 
As a matter of fact, we show that Sol-Eng interacts with Met by coimmunoprecipitation 
experiments (Fig. 5F, G). Because Met can associate with different membrane proteins, 
including integrins, the hyaluronan receptor CD44 and plexins (23), the question 
whether Sol-Eng binds Met directly or indirectly remains to be investigated. 
Intriguingly, full-length endoglin while coimmunoprecipitating with Met (Fig. 5G) was 
unable to downmodulate it and prevent its signaling activity.  
 Spindle carcinoma cell lines exhibit a high ratio of active phosho-Met respect to 
total Met protein levels compared with cell lines corresponding to earlier stages of 
tumor progression (Fig. 4F). This is due to the fact that spindle carcinoma cells tend to 
express higher levels of HGF. Indeed, elevated expression of HGF appears to be a 
hallmark of malignant progression during mouse skin carcinogenesis in vivo, since HGF 
levels increase during progression from papillomas to SCCs and are further enhanced in 
SpCCs (Fig. 4B). High levels of HGF in the serum of breast cancer patients correlate 
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with shorter disease-free survival and increased metastasis in lymph nodes (39, 40). In 
this respect, skin spindle cell carcinomas (represented by the CarC cell line) resemble 
claudin-low, basal-type breast carcinomas (41), where Met activation is associated with 
high aggressiveness and poor patient outcome (42, 43). 
 In summary, our results suggest that Sol-Eng antagonizes Met signaling activity 
at advanced stages of carcinogenesis. These data together with the anti-angiogenic 
action ascribed to Sol-Eng (12, 14, 17) point to a malignancy suppressor role for this 
circulating form of endoglin. Paradoxically, the levels of Sol-Eng increase at later stages 
of carcinogenesis and correlate with bad prognosis in human epithelial cancer (2, 4). It 
could be argued that Sol-Eng cannot counteract the full malignant strength displayed in 
the tumor microenvironment at late stages of carcinogenesis. In addition, Sol-Eng might 
act by preventing the development of cancer in premalignant stages. Supporting this 
view there is epidemiological evidence indicating that preeclamptic women expressing 
elevated levels of placental Sol-Eng are protected against the development of different 
types of cancer, including breast carcinomas, in later life. Nonetheless, there are 
dissenting reports on this matter (reviewed in ref. 44). Further studies are necessary to 
understand the role of soluble endoglin on tumor initiation and progression. 
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Legends to Figures 
Figure 1. Sol-Eng inhibits CarC cell proliferation. CarC cells were transfected with a 
cDNA encoding Sol-Eng tagged with HA. Two clones (CSE1 and CSE3) were selected 
for further studies. Pooled CarC cells transfected with the empty vector (mock) were 
used as a control. (A) Western blot analysis of HA-Sol-Eng protein levels expressed by 
the transfectants. (B) The levels of HA-Sol-Eng secreted by the cells into the 
conditioned media were determined by ELISA, as described in Materials and methods. 
(C and D) Cell growth assays in the presence (C) or absence (D) of serum. In C, 
~10,000 cells were seeded and grown in medium plus 10% FBS. Proliferation was 
determined by incorporation of BrdU into DNA, as described in Materials and methods. 
In D, ~30,000 cells were seeded and grown in medium in the absence of serum. The 
relative number of cells was determined by crystal violet staining at the indicated times. 
Columns in C and D represent the average of triplicate determinations + SEM, and 
values are represented as percentages with respect to mock (C) and time zero (D). (E) 
Cell proliferation assays measured by incorporation of BrdU into DNA of mock and 
CSE3 cells pre-incubated or not with purified rhSol-Eng (100 ng/ml). p-values were 
obtained using the Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001 
Figure 2. Sol-Eng inhibits basal MAPK signaling activity in CarC cells and tumors. (A) 
Tumorigenic potential of mock and CSE cells. Cells were injected into the two flanks of 
athymic nude mice, and the size of tumors were measured periodically. The graph 
shows one representative experiment out of two independent ones. (B) The expression 
of HA-Sol-Eng was determined by Western blotting in two different tumors induced by 
each cell transfectant at 43 days post-injection. (C and D) Western blot analysis of 
ERK1/2 phosphorylation relative to the total expression levels in cell (C) and tumor (D) 
lysates. GAPDH was used as a loading control. Tumors analyzed were the same as in B.   
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Figure 3. Sol-Eng impairs TGF- stimulation of CarC cell growth and MAPK signaling 
activity. (A) Cell growth assay in the presence of TGF-1. Mock and CSE3 cells 
(~30,000) were seeded in culture dishes in the absence of serum and treated with the 
indicated concentrations of TGF-1 for 48 h. Then, cell number was determined by 
crystal violet staining. Values are represented as percentages with respect to treatment 
with vehicle. p-values were obtained using the Student’s t test. *p < 0.05. (B) Western 
blot analysis of ERK1/2 phosphorylation relative to the total ERK1/2 expression levels 
of mock and CSE3 cells at different times of treatment with 1 ng/ml TGF-1. (C) 
Western blot analysis of ERK1/2 phosphorylation relative to the total expression levels 
of ERK1/2 of CarC cells untreated and treated with 1 ng/ml TGF-1 for 30 min, pre-
incubated or not with purified rhSol-Eng (25 ng/ml) for 1 h. In B and C, GAPDH was 
used as a loading control.  
Figure 4. HGF and Met expression during mouse skin carcinogenesis. (A and B) 
Transcriptional expression of HGF in mouse epidermal cell lines (A) and skin tumors 
induced by DMBA/TPA (B). (C and D) Transcriptional expression of Met in mouse 
epidermal cell lines (C) and skin tumors induced by DMBA/TPA (D). Normalized HGF 
and Met transcript levels were measured by real-time quantitative RT-PCR relative to 
RPLPO. Ep, normal epidermis; Pap, papilloma; SCC, squamous cell carcinoma; SpCC, 
spindle cell carcinoma; w, weeks. (E) Western blot analysis of Met phosphorylation 
relative to the total Met expression levels in mouse epidermal cell lines. Two different 
exposure times for Met are shown. Values indicated at the bottom represent the ratio of 
active Met vs total Met levels. The intensities of phospho-Met and Met bands in the blot 
were quantified by densitometric analysis and normalized to GAPDH, used as a control 
for protein loading.    
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Figure 5. Sol-Eng coimmunoprecipitates with Met and attenuates basal and HGF-
induced Met signaling activity. (A) Western blot analysis of basal Met phosphorylation 
relative to the total Met expression levels in mock, CSE1 and CSE3 cells. (B and C) 
Western blot analysis of phospho-Met, Met, phospho-ERK1/2 and ERK1/2 in mock and 
CSE1 (B) or CSE3 (C) cells after stimulation with 20 ng/ml HGF for the indicated 
times. (D) Western blot analysis of phospho-Met, Met, phospho-ERK1/2, ERK1/2 in 
CarC cells untreated or treated with 20 ng/ml HGF for 5 min, pre-incubated with the 
indicated concentrations of purified rhSol-Eng for 1 h. The discontinuous line indicates 
that lanes fifth and sixth are not contiguous but belong to the same gel (see 
Supplementary Figure 6A, available at Carcinogenesis Online). (E) Western blot 
analysis of phospho-Met, Met, phospho-ERK1/2, ERK1/2 and endoglin (Eng) in CarC 
cells stably transfected with a cDNA encoding full-length endoglin (CarC-Eng) or the 
empty vector (CarC-neo) after stimulation with 20 ng/ml HGF for the indicated times. 
GAPDH was used as a loading control. (F) HEK293T cells were transiently 
cotransfected with Met and HA-tagged Sol-Eng. After 24 h of transfection, the indicated 
amounts of total lysates were immunoprecipitated with anti-Met Ab (upper panel), anti-
HA mAb (lower panel) and rat IgG as a control. Immunopreciptates were subjected to 
SDS-PAGE electrophoresis and immunoblotted with anti-HA (upper panel) and anti-
Met (lower panel) antibodies. The presence of Met and HA-Sol-Eng in the precipitates 
were determined with the corresponding antibodies. (G) HEK-293T cells were 
transiently cotransfected with untagged full-length, wild type c-Met and either full-
length Eng (Eng) or Sol-Eng, both tagged with HA. After 24 h of transfection, total 
lysates were immunoprecipitated with anti-Met Ab or rabbit IgG as a control. 
Immunopreciptates were subjected to SDS-PAGE electrophoresis and immunoblotted 
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with anti-HA mAb. The presence of Met in the precipitate was determined with anti-
Met Ab.    
Figure 6. Sol-Eng but not full-length Eng inhibits stimulation of CarC cell migration 
and invasion by HGF. (A and B) Transwell migration assays through uncoated (A) and 
Matrigel-coated (B) filters of parental CarC, CarC-neo and CarC-Eng cells. (C and D) 
Transwell migration assays through uncoated (C) and Matrigel-coated (D) filters of 
mock and CSE3 cells. HGF (100 ng/ml) was used as a chemoattractant. Migrated cells 
on the underside of the filter were fixed, stained with DAPI and counted. Values are 
represented as percentages with respect to unstimulated CarC cells. p-values were 
obtained using the Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001; ns, non-
significant. Panels below the graphics show representative examples of 
migrated/invaded cells stained with DAPI.    
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Supplementary Figure Legends 
Supplementary Figure 1. Hypothetical model for the role of Sol-Eng on the 
HGF/Met/MAPK pathway. (A) The binding of HGF to the extracellular region of Met 
induces its dimerization and subsequent autophosphorylation in several tyrosines 
located in the juxtamembrane domain, the kinase domain and the C-terminal docking 
site. Phosphorylation of Met leads to recruitment of adaptor proteins and activation of 
downstream signaling pathways, including MAPK, which induces biological responses. 
Phosphorylation of Met also induces clathrin-dependent internalization of the receptor 
via early endosomes and its subsequent degradation in lysosomes. Met endocytosis is 
not only required for Met degradation but also favors signal transduction (Lefebvre et 
al. 2012, FASEB J., 26, 1387-99). (B) When the levels of Sol-Eng are increased due to 
the proteolytic shedding of membrane endoglin (that may occur in tumor as well as in 
stromal cells), Sol-Eng binds Met preventing its dimerization and activation by HGF. 
The binding of Sol-Eng also induces Met degradation by an unknown mechanism, 
which might involve internalization and lysosomal degradation (as depicted in the 
figure for simplicity) or not. Whether Sol-Eng is co-internalized with Met remains to be 
determined. 
Supplementary Figure 2. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 1A. (B) 
Uncropped images of Western blots in Figure 2B. (C) Uncropped images of Western 
blots in Figure 2C.  
Supplementary Figure 3. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 2D. (B) 
Uncropped images of Western blots in Figure 3B. 
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Supplementary Figure 4. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 3C. (B) 
Uncropped images of Western blots in Figure 4E. (C) Uncropped images of Western 
blots in Figure 5A. 
Supplementary Figure 5. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 5B. (B) 
Uncropped images of Western blots in Figure 5C. 
Supplementary Figure 6. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 5D. (B) 
Uncropped images of Western blots in Figure 5E. 
Supplementary Figure 7. Uncropped images corresponding to the immunoblots 
included in figures. (A) Uncropped images of Western blots in Figure 5F, upper panel. 
(B) Uncropped images of Western blots in Figure 5F, lower panel. (C) Uncropped 
images of Western blots in Figure 5G. 
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